Kornimate/medical-research-clean huggingface dataset:
pain coping skills and meaning-centered intervention

Conditions: Advanced Cancer; Pain

Summary: the proposed study seeks to develop and test a novel psychosocial pain management intervention for patients with advanced cancer. it is hypothesized that the intervention will demonstrate feasibility, acceptability, and preliminary efficacy. the first aim is to develop a combined pain coping skills training and meaning-centered psychotherapy intervention. the second aim is to test the intervention's feasibility and acceptability as well as preliminary efficacy for improving primary outcomes (i.e., pain, pain interference, and meaning in life) and secondary outcomes. two efficacious, theory-driven interventions will be integrated to address pain management by teaching pain coping skills with a novel emphasis on enhancing a sense of meaning in life. participants will be patients with advanced cancer and moderate-to-severe pain. the study will be conducted in two phases. phase i of the study will be intervention development. the intervention content will be guided by theory and mentoring from a team of leading experts in pain management and meaning-centered psychotherapy. initial intervention content will be further informed by interviews with patients with advanced cancer. content will then be refined through an iterative patient testing process. phase ii of the study will be a single-arm pilot trial testing the intervention. the intervention will be delivered in-person and consist of four, 45-to-60 minute therapy sessions delivered using videoconferencing technology. study measures will be collected at baseline (0 weeks), immediately post-intervention (5 weeks), and 4-weeks post-intervention (9 weeks).

effective pain management is a major healthcare concern for patients with advanced cancer. compared to patients with early-stage disease, those with advanced cancer report higher levels of pain and greater functional impairment related to pain. there is a critical need for psychosocial pain management interventions that are specifically designed to address the suffering of patients with advanced cancer. the proposed study seeks to develop and assess the feasibility, acceptability, and preliminary efficacy of a novel integration of pain coping skills training and meaning-centered psychotherapy for patients with advanced cancer and moderate-to-severe pain.

Eligibility criteria:
inclusion criteria: * stage iv solid tumor cancer diagnosis; or stage iii pancreatic or lung cancer diagnosis * at least moderate pain (pain score \>/= 4) at recruitment * clinically elevated distress (nccn distress thermometer \>/= 3) at recruitment * eastern cooperative oncology group (ecog) \</= 2 at recruitment * ability to speak and read english exclusion criteria: * brain tumor diagnosis * significant cognitive impairment * serious mental illness that would interfere with engagement in the intervention (e.g., schizophrenia)
study using cp-751,871 in patients with stage iv colorectal cancer that has not responded to previous anti-cancer treatments

Conditions: Colorectal Neoplasm

Summary: this study will test if there is any survival benefit in patients with refractory metastatic colorectal cancer that receive cp-751, 871.


Eligibility criteria:
inclusion criteria: * patients who have stage iv colorectal cancer * patients whose disease has worsened despite prior anti-cancer therapy * patients who have satisfactory bonemarrow, kidney and liver function exclusion criteria: * patients who are being simultaneously treated with another anti-cancer therapy. * patients who have previously received anti-cancer therapy that works like cp-751, 871 (targets insulin-like growth factor receptor) * patients that are pregnant or breast-feeding

Keywords: refractory colorectal single arm phase 2
the effect of the mobile application developed for hemodialysis patients on symptoms and disease compliance

Conditions: Chronic Kidney Failure

Summary: the aim of this study is to determine the effect of mobile-based education and counseling developed for hemodialysis patients on the symptoms experienced and the adaptation to the disease.

patients with end-stage renal disease are faced with many symptoms both during the disease and during the hemodialysis treatment process. likewise, this process brings with it problems of adaptation to the disease. experiencing intense symptoms negatively affects compliance with the disease and hemodialysis treatment, and compliance problems complicate symptom management. therefore, patients need information support that can increase symptom management and compliance. considering today's technology, this information can be provided by mobile phone, especially due to ease of use and fast transportation. in order for patients to access accurate information and receive consultancy from experts, appropriate software and sustainable mobile applications must be included in the disease management process. today, mobile applications are an integral part of daily life for millions of users worldwide and are increasingly used to receive and communicate fast and interactive information about various chronic diseases. with the mobile-based training and counseling to be applied in this study, it is aimed to enable patients receiving hemodialysis treatment to access professional information support more easily, to better manage the symptoms they experience due to the disease, and to increase their adaptation to the disease. for this reason, the effect of mobile-based training and counseling developed for patients receiving hemodialysis treatment on the symptoms experienced by the patients and their adaptation to the disease will be evaluated in this study.

Eligibility criteria:
inclusion criteria: * chronic kidney failure patient * agreeing to be a voluntary participant, * receiving dialysis treatment for at least 3 months, * 18 years and over, * able to understand and speak turkish * at least primary school graduate, * using a smart phone for at least one year, * having internet access at home or at work. * able to use internet exclusion criteria: * speech, hearing and visual impairment, * having any psychiatric diagnosis or treatment that may interfere with perception (alzheimer, schizophrenia, major depression) * rheumatological diseases, fracture, joint health problem, amputation

Keywords: hemodialysis treatment compliance symptom managemen mobile application chronic kidney failure
characteristics of pulmonary vascular changes in patients with kidney transplantation

Conditions: Pulmonary Hypertension; Kidney Transplantation; Haemodialysis

Summary: the aim of the study is to investigate pulmonary hemodynamics at rest and during exercise in patients before and after kidney transplantation.


Eligibility criteria:
inclusion criteria: * age: ≥ 18 years * patients listed for first kidney transplantation at the clinical division of nephrology exclusion criteria: * age \< 18 years * combined organ transplantations (heart-kidney, pancreas-kidney etc.) * patients with prior kidney transplantation * high calcium score on cardiac-ct (\> 160 agatston score)

Keywords: pulmonary hypertension kidney transplantation vascular remodeling echocardiography pulmo-renal axis
ultrasound guided local infiltration analgesia for hip arthroscopy

Conditions: Hip Injuries

Summary: this study is being undertaken to compare the pain control using either bupivacaine versus liposomal bupivacaine. liposomal bupivacaine can potentially provide pain relief lasting up to 72 hours while regular bupivacaine can provide pain relief up to 12 hours

patients undergoing hip arthroscopy experience moderate to severe postoperative pain. effective pain control after surgery is an important component in the overall management of these patients. good pain control encourages early participation in rehabilitation program, increases success of the surgery, and improves patient satisfaction. typically, postoperative analgesia is provided to these patients either with nerve blocks or opioid medications. both these methods provide good pain relief but nerve blocks are associated with weakness of lower extremity muscles which interferes with early ambulation and increase the risk of falls while narcotic medications increase the risk of nausea, vomiting, itching, constipation, ileus, urinary retention, sedation and respiratory depression.

Eligibility criteria:
inclusion criteria: * patients having hip arthroscopy exclusion criteria: * history of neurologic disease, neuropathy, diabetes * allergy to local anesthetic solution * chronic use of narcotics * inability to give consent/cooperate with study * history of previous hip arthroscopy on the ipsilateral side * pregnancy

Keywords: hip arthroscopy liposomal bupivacaine bupivacaine
the effect of patient position changes on advanced cardiac indices in cancer surgery

Conditions: Abdominal Cancer; Blood Pressure; Cardiac Indices

Summary: esophageal doppler monitoring (deltex cardioq esophageal doppler monitor, odm) is used to manage patients' fluid therapy by non-invasively measuring continuous cardiac output with an esophageal probe. the aim of this study was to compare the effects of patient position changes on cardiac indices and vital signs in patients who underwent major abdominal cancer surgery with laparoscopic and open surgery using odm.

patients who underwent major abdominal cancer surgery using odm in the operating room of our hospital between november 2021 and november 2022 were identified from the anesthesiology clinic records and examined according to whether they were operated with open or closed (laparoscopic) methods. demographic data, vital signs, amount of bleeding, type and amount of fluid administered, and the results of cardiac index measurements performed with the odm device in the supine and trendelenburg positions (45 degrees) were analyzed. parameters recorded with the odm device; co: cardiac output, ftc: flow time corrected, pv: peak velocity, sd: stroke distance.

Eligibility criteria:
inclusion criteria: * elective operation * asa 1-4 exclusion criteria: * heart failure * valvular heart disease, * patients with symptomatic rhythm disturbances * odm placement contraindicated (coagulopathy, oesophageal varices, known aortic aneurysm)
safety & efficacy of omega-3 fish oil in overweight children & adolescents

Conditions: Overweight; Obesity

Summary: children with an excess in body weight, increase the risk of obesity-related co-morbidities and cardiovascular diseases. childhood obesity may be due to diets laden with fat and lack of physical activity. omega-3 fish oil is a supplementation that may promote a greater reduction of pro-inflammatory mediators; combined with exercise and nutritional regimens it may also help improve glycemic, lipid markers, and body composition in overweight children and adolescents.


Eligibility criteria:
inclusion criteria: * between 8-18 years old * bmi ≥95th percentile * patient \& parent/guardian consent to participate * attendance of risk factor reduction lifestyle modification program exclusion criteria: * major surgical procedure within 1 year * significant cardiovascular disease or other morbidity that preclude patients from following dietary regimen or exercising. * mentally challenged * currently taking fish oil supplements, unless 1 month wash-out period is achieved. * diabetes

Keywords: overweight obesity fish oil
efficacy and safety of direct oral anticoagulants for the treatment of mural thrombus

Conditions: Acute Myocardial Infarction

Summary: to describe the prescribing patterns at methodist dallas medical center (mdmc) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of doacs apixaban, dabigatran, and rivaroxaban in comparison to warfarin. with limited treatment guideline consensus, minimal evidence to support the use of doacs for left atrial appendage (laa) thrombus and left ventricular thrombus (lvt), and a lack of evidence for the use of doacs in aortic thrombus, further research is warranted to determine the role of doacs in the treatment of various mural thrombi in comparison to warfarin.

retrospective chart review of mdmc patients from 4/1/2017 to 8/31/19 with newly diagnosed mural thrombus. 3.1. study methods * patients will be allocated into two groups: those who were prescribed doacs upon discharge and those who were prescribed warfarin upon discharge * subgroup analyses will occur to evaluate the difference in efficacy and safety endpoints for patients into four categories including: those predisposed to mural thrombus by baseline risk factors (afib vs. acs), location of the mural thrombus (atrial, ventricular, aortic), doac by agent (apixaban, rivaroxaban, dabigatran), and doac by scheduled dosing indication (afib vs. vte).

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. mhs patients with newly diagnosed mural thrombus from 4/1/2017 to 8/31/19 identified by international classification of diseases (icd) codes: i23.6, i240, i513, i7409, i7411, i7419, i82210, i82229 exclusion criteria: 1. age \<18 years 2. anticoagulant use at baseline (doac, lmwh, vka) 3. active cancer 4. active bleeding 5. pregnancy 6. hospice or palliative care upon discharge 7. warfarin that did not receive adequate bridging from parenteral anticoagulation 8. non newly diagnosed mural thrombus
transbronchial catheter aspiration and transbronchial needle aspiration in the diagnosis of lung cancer

Conditions: Lung Cancer

Summary: the aim of this study is prospectively to determine the diagnostic sensitivity of transbronchial catheter aspiration (tbca) in comparison with transbronchial needle aspiration (tbna) in the diagnosis of peripheral nodules and masses of the lung.

the yield of transbronchial forceps biopsy under fluoroscopy in the diagnosis of peripheral lesion of the lung lies between 32 and 57%. several studies prove an amelioration of success rates by addition of cytological methods such as tbna, tbca and bronchial brushing. furthermore, for tbna and tbca a significantly higher yield was reported in comparison with transbronchial forceps biopsy. tbna and tbca are routinely used methods, both techniques are safe, the instruments used are certificated.

Eligibility criteria:
inclusion criteria: * informed consent prior to the procedure * radiologically peripheral pulmonary lesions between 10 and 60 millimeters in diameter exclusion criteria: * endoscopically visible lung carcinoma * no consent in further diagnostic procedures, when bronchoscopy fails to establish a diagnosis * haemorrhagic syndrome; grave cardiac disease; oxygen saturation lower than 90 percent

Keywords: lung cancer transbronchial biopsy transbronchial catheter aspiration transbronchial needle aspiration peripheral pulmonary lesion bronchoscopy
feasibility and toxicity of degarelix for prostate downsizing prior to permanent seed prostate brachytherapy

Conditions: Prostate Cancer

Summary: this study will investigate the efficacy of degarelix, a luteinizing hormone releasing hormone (lhrh) antagonist, to reduce prostate volume prior to permanent seed prostate brachytherapy. there are 2 eligible populations of men, all of whom will have selected brachytherapy as their treatment of choice for their prostate cancer. either they have an enlarged prostate that requires size reduction to render brachytherapy technically feasible, or they require androgen ablation in conjunction with brachytherapy for optimal tumor control. the hypothesis is that degarelix will provide \> 30% volume reduction by 3 months in \> 30% of men.

all men will have a baseline transrectal ultrasound for brachytherapy planning that has demonstrated an enlarged prostate with or without pubic arch obstruction. after signing the informed consent document they will have a loading dose of 240 mg degarelix and then monthly maintenance dose injections of 80 mg until such time as sufficient prostate reduction has occured (2-3 months) or they complete the 6 months of required androgen ablation for their disease status.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of prostate cancer * favorable risk disease (ct1 or t2a, gleason score (gs) 6, and prostate specific antigen (psa) \< 10 ng/ml) * low-tier intermediate risk disease (ct2c,gs=6,and psa 10-15 ng/ml, or gs=7 and psa \< 10 ng/ml) * intermediate risk disease and androgen deprivation therapy recommended by the treating physician for oncologic reasons such as (≥ 50% positive biopsy cores,ct2c,psa 15-20 ng/ml,gs=7) * patient requires baseline planning trans-rectal ultrasound for the purposes of prostate brachytherapy, showing prostate volume \> 40 ml and pubic arch interference (not required for those requiring androgen ablation for oncologic reasons) exclusion criteria: * castrate serum testosterone level * previous or concurrent pelvic radiotherapy * unable to give written informed consent * contraindications to permanent seed prostate brachytherapy or to androgen deprivation therapy * prior treatment for prostate cancer * prior trans-urethral resection of the prostate * previous therapy with a 5-α reductase inhibitor, anti-androgen agent, or lhrh agonist * previous therapy with degarelix

Keywords: prostate neoplasm brachytherapy androgen ablation benign prostatic hypertrophy prostate size reduction localized prostate cancer with prostate volume > 40 cc
information and acceptability of biosimilars

Conditions: Rheumatoid Arthritis; Spondyloarthritis; Psoriatic Arthritis

Summary: patients with rheumatoid arthritis or spondyloarthritis, currently treated or about to be started with anti-tnf original drug adalimumab or etanercept will be included and randomized to either " information leaflet only " or " information leaflet + nurse information " arms, just before they see their rheumatologist for periodic assessment of disease and treatment. patients from the " information leaflet only " arm will be distributed individually a dedicated leaflet with written generic informations about the use of biosimilars in rheumatic diseases (individual and societal advantages, pharmaceutical development, scientific efficacy and safety results). patients from the " " information leaflet + nurse information " arm will be delivered the same leaflet, and additionally offered to have a dedicated individual interview with a specialist nurse, who will orally discuss informations about biosimilars based on a standardized talk, completed by answers to any questions by the patient. the rheumatologist will then propose, unless inappropriate based on clinical evaluation of the patient, a change in the treatment of patients from the original drug to the corresponding biosimilar. the primary outcome will be the observed proportions of patients actually receiving the biosimilar drug at the 6-months follow-up visit in the 2 compared arms. secondary outcomes will be average time spent by the nurse to adequatley inform the patient, the proportion of patients from the intervention arm who have actually asked for the nurse information interview, and the reasons for refusal of biosimilars, when appropriate.


Eligibility criteria:
inclusion criteria: * age 18 and over (no upper age limit) * all adult patients seen in rheumatology consultation at the montpellier hospital * with inflammatory rheumatism (rheumatoid arthritis or spondyloarthritis). * treated (or in the process of being treated at the end of the consultation) by etanercept or adalimumab * in whom the biomedical treatment already used should in principle be renewed without modification (patient deemed good responder and well tolerant of the treatment) * or where biomedical initiation has just been indicated during the consultation * member of a social security scheme * informed and written consent exclusion criteria: * unable to understand information (not fluent in the french language, severe cognitive impairment, etc.) * known intolerance to one of the proposed biosimilar excipients * vulnerable persons: pregnant woman, minor patient, deprived of liberty, under guardianship or under curatorship

Keywords: rheumatoid arthritis spondyloarthritis biologics biosimilars information
a study of an approved vaccine at mumps expiry potency in healthy children 12 to 18 months of age (v205c-007)(completed)

Conditions: Measles; Mumps; Rubella; Varicella

Summary: the purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.


Eligibility criteria:
inclusion criteria: * healthy children 12 to 18 months of age exclusion criteria: * history or prior exposure to measles, mumps, rubella or varicella * history of anaphylactoid reactions or hypersensitivity to any component of the vaccine, including gelatin and neomycin
usage of multiple drugs in treatment of postoperative vomiting after laparoscopic appendectomy

Conditions: to Treat the Vomiting Frequently Occur Post-laparoscopic by Different Anti Emetic Drugs

Summary: to compare and evaluate the antiemetic effect and the safety of ondansetron, inhalational isopropyl alcohol and super hydration on adult patients after laparoscopic appendectomy.

this prospective double-blind study done on 240 patients admitted to surgical i.c.u after laparoscopic appendectomy. those who had preoperative koivuranta vomiting score of more than 3 enrolled in our study. every group contains 80 patients. patients of group a received ondansetron 4 mg intravenous immediately once reached to i.c.u and another same dose after 6 hours while patients of group b received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours. the last group c received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours. the duration of the study was 24 hours post-operatively. as ponv is self-limited within 24 hours.

Eligibility criteria:
inclusion criteria: postoperative nausea and vomiting exclusion criteria: systemic disease as diabetes or hypertension local gastric diseases